- Home
- SONO vs VERA Comparison
SONO vs VERA Comparison
Compare SONO & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONO
- VERA
- Stock Information
- Founded
- SONO 2002
- VERA 2016
- Country
- SONO United States
- VERA United States
- Employees
- SONO N/A
- VERA N/A
- Industry
- SONO Consumer Electronics/Video Chains
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- SONO Consumer Discretionary
- VERA Health Care
- Exchange
- SONO Nasdaq
- VERA Nasdaq
- Market Cap
- SONO 1.2B
- VERA 2.0B
- IPO Year
- SONO 2018
- VERA 2021
- Fundamental
- Price
- SONO $10.75
- VERA $24.00
- Analyst Decision
- SONO Buy
- VERA Buy
- Analyst Count
- SONO 3
- VERA 8
- Target Price
- SONO $13.00
- VERA $64.63
- AVG Volume (30 Days)
- SONO 1.6M
- VERA 2.2M
- Earning Date
- SONO 08-06-2025
- VERA 08-07-2025
- Dividend Yield
- SONO N/A
- VERA N/A
- EPS Growth
- SONO N/A
- VERA N/A
- EPS
- SONO N/A
- VERA N/A
- Revenue
- SONO $1,463,138,000.00
- VERA N/A
- Revenue This Year
- SONO N/A
- VERA N/A
- Revenue Next Year
- SONO $3.27
- VERA N/A
- P/E Ratio
- SONO N/A
- VERA N/A
- Revenue Growth
- SONO N/A
- VERA N/A
- 52 Week Low
- SONO $7.63
- VERA $18.53
- 52 Week High
- SONO $15.89
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- SONO 65.48
- VERA 54.33
- Support Level
- SONO $9.65
- VERA $22.76
- Resistance Level
- SONO $11.39
- VERA $23.97
- Average True Range (ATR)
- SONO 0.37
- VERA 1.21
- MACD
- SONO 0.11
- VERA 0.15
- Stochastic Oscillator
- SONO 95.98
- VERA 73.63
About SONO Sonos Inc.
Sonos Inc is engaged in providing home sound systems. The company's product profile includes speaker sets and other accessories like boost, mounts, stands, and cables and networking. Geographically, the company operates in the Americas, Europe, the Middle East and Africa and the Asia Pacific. Generating a majority of its revenue from the Americas.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.